Study on Organoids for Type 1 Diabetes Therapy

Overview of Type 1 Diabetes

A recent study investigated the potential of organoids formed by combining islet cells with human amniotic epithelial cells as a viable cell-based therapy for type 1 diabetes. This chronic disease often manifests early in life and involves the autoimmune destruction of pancreatic beta cells, leading to insufficient insulin production necessary for blood glucose regulation. If untreated, type 1 diabetes can result in severe long-term complications such as neuropathy, retinopathy, and renal failure. Although insulin therapy remains the standard treatment, it does not fully prevent these complications.

Using Organoids as a Therapeutic Tool for Diabetes

Organoids are miniature, three-dimensional tissue cultures derived from stem cells, designed to mimic the complexity of an organ or express specific organ functionalities. Researchers have successfully created organoids that differentiate into insulin-producing pancreatic cells, which effectively regulated blood glucose levels when transplanted into diabetic mice.

Islet Cell Transplantation for Diabetes Treatment

Islet cells, responsible for insulin production in the pancreas, are central to type 1 diabetes treatment through transplantation. This cell therapy has shown potential for effective glucose level control; however, challenges remain due to the loss of islet cells post-transplantation. This loss often results from inflammation at the transplant site and disruptions in blood and oxygen supply, leading to cell death. Consequently, scientists are exploring new strategies to enhance islet cell survival and improve transplantation outcomes.

Engineering Insulin-Producing Organoids

Amniotic epithelial cells, known for their high proliferative capacity, self-renewal ability, and multilineage differentiation, have garnered significant attention in regenerative medicine. In a study published in *Nature Communications*, researchers from Geneva, Switzerland, successfully engineered functional insulin-producing organoids by combining human amniotic epithelial cells with dissociated islet cells. The research aimed to assess whether the inclusion of amniotic epithelial cells could enhance islet cell engraftment and viability in mouse models.

Functionality of Engineered Organoids After Transplantation

The study found that the organoids created from human amniotic epithelial and islet cells experienced no loss of islet cells following transplantation. A protective effect of amniotic epithelial cells on islet cells under hypoxic conditions was observed, with the organoids maintaining glucose responsiveness and demonstrating significant protection against cell death.

Impact of Islet Organoids on Glucose Regulation

The researchers noted that the islet organoids enriched with human amniotic epithelial cells led to substantial engraftment of insulin-producing beta cells, enhancing their functionality. In comparison to islet cell organoids without amniotic epithelial cells, the combined organoids successfully normalized blood glucose levels in diabetic mice, indicating effective blood glucose regulation.

Future Potential of Cell-Based Therapy for Type 1 Diabetes

These findings underscore the enhanced functionality and viability of islet cells when combined with human amniotic epithelial cells, improving successful engraftment. This innovative cell therapy shows promise as a potential treatment strategy for type 1 diabetes. The researchers advocate for further exploration of these organoids, including the investigation of favorable implantation sites and the use of stem cells as a limitless source of insulin.

Written by Preeti Paul, M.Sc.

Reference: Fanny Lebreton et al., Insulin producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nature Communications 10, Article number: 4491 (2019)

Image by Steve Buissinne from Pixabay